Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial to Determine Safety and Tolerability of Ex Vivo Expanded Human Myeloid Progenitor Cells (CLT-008) Infused 24 Hours Post-Transplant to Support Allogeneic Umbilical Cord Blood Transplantation for Hematologic Malignancies

NCT00891137 is registered in ClinicalTrials.gov with Cellerant Therapeutics as lead sponsor.

NCT NCT00891137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00891137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial to Determine Safety and Tolerability of Ex Vivo Expanded Human Myeloid Progenitor Cells (CLT-008) Infused 24 Hours Post-Transplant to Support Allogeneic Umbilical Cord Blood Transplantation for Hematologic Malignancies
Lead sponsor
Cellerant Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2009
Completion date
June 30, 2014
Enrollment
30 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, plasma cell neoplasm